Literature DB >> 9151854

The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells.

J H Ahn1, G S Hayward.   

Abstract

The major immediate-early (MIE) gene products of human cytomegalovirus (HCMV) are nuclear phosphoproteins that are thought to play key roles in initiating lytic cycle gene regulation pathways. We have examined the intranuclear localization pattern of both the IE1 and IE2 proteins in virus-infected and DNA-transfected cells. When HCMV-infected human diploid fibroblast (HF) cells were stained with specific monoclonal antibodies, IE1 localized as a mixture of nuclear diffuse and punctate patterns at very early times (2 h) but changed to an exclusively nuclear diffuse pattern at later times. In contrast, IE2 was distributed predominantly in nuclear punctate structures continuously from 2 to at least 12 h after infection. These punctate structures resembled the preexisting PML-associated nuclear bodies (ND10 or PML oncogenic domains [PODs]) that are disrupted and dispersed by the IE110 protein as a very early event in herpes simplex virus (HSV) infection. However, HCMV differed from HSV by leading instead to a change in both the PML and SP100 protein distribution from punctate bodies to uniform diffuse patterns, a process that was complete in 50% of the cells at 2 h and in 90% of the cells by 4 h after infection. Confocal double-label indirect immunofluorescence assay analysis confirmed that both IE1 and IE2 colocalized transiently with PML in punctate bodies at very early times after infection. In transient expression assays, introduction of IE1-encoding plasmid DNA alone into Vero or HF cells produced the typical total redistribution of PML into a uniform nuclear diffuse pattern together with the IE1 protein, whereas introduction of IE2-encoding plasmid DNA alone resulted in stable colocalization of the IE2 protein with PML in the PODs. A truncated mutant form of IE1 gave large nuclear aggregates and failed to redistribute PML, and similarly a deleted mutant form of IE2 failed to colocalize with the punctate PML bodies, confirming the specificity of these effects. Furthermore, both Vero and U373 cell lines constitutively expressing IE1 also showed total PML relocalization together with the IE1 protein into a nuclear diffuse pattern, although a very small percentage of the cells which failed to express IE1 reverted to a punctate PML pattern. Finally, the PML redistribution activity of IE1 and the direct association of IE2 with PML punctate bodies were both confirmed by infection with E1A-negative recombinant adenovirus vectors expressing either IE1 or IE2 alone. These results confirm that transient colocalization with and disruption of PML-associated nuclear bodies by IE1 and continuous targeting to PML-associated nuclear bodies by IE2 are intrinsic properties of these two MIE regulatory proteins, which we suggest may represent critical initial events for efficient lytic cycle infection by HCMV.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9151854      PMCID: PMC191682     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Human cytomegalovirus ie1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element.

Authors:  J M Cherrington; E S Mocarski
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

2.  Herpes simplex virus genes involved in latency in vitro.

Authors:  J Russell; N D Stow; E C Stow; C M Preston
Journal:  J Gen Virol       Date:  1987-12       Impact factor: 3.891

3.  A deletion mutant in the human cytomegalovirus gene encoding IE1(491aa) is replication defective due to a failure in autoregulation.

Authors:  E S Mocarski; G W Kemble; J M Lyle; R F Greaves
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  Reactivation of latent herpes simplex virus by adenovirus recombinants encoding mutant IE-0 gene products.

Authors:  X X Zhu; J X Chen; C S Young; S Silverstein
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

5.  Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest.

Authors:  F M Jault; J M Jault; F Ruchti; E A Fortunato; C Clark; J Corbeil; D D Richman; D H Spector
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies.

Authors:  L Szekely; K Pokrovskaja; W Q Jiang; H de The; N Ringertz; G Klein
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

7.  Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties.

Authors:  P P Pandolfi; F Grignani; M Alcalay; A Mencarelli; A Biondi; F LoCoco; F Grignani; P G Pelicci
Journal:  Oncogene       Date:  1991-07       Impact factor: 9.867

8.  The IE2 regulatory protein of human cytomegalovirus induces expression of the human transforming growth factor beta1 gene through an Egr-1 binding site.

Authors:  Y D Yoo; C J Chiou; K S Choi; Y Yi; S Michelson; S Kim; G S Hayward; S J Kim
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins.

Authors:  P Kastner; A Perez; Y Lutz; C Rochette-Egly; M P Gaub; B Durand; M Lanotte; R Berger; P Chambon
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

10.  Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein.

Authors:  C Hagemeier; R Caswell; G Hayhurst; J Sinclair; T Kouzarides
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598

View more
  138 in total

1.  Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0.

Authors:  W E Hobbs; N A DeLuca
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Roles for the E4 orf6, orf3, and E1B 55-kilodalton proteins in cell cycle-independent adenovirus replication.

Authors:  F D Goodrum; D A Ornelles
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

3.  Efficient activation of viral genomes by levels of herpes simplex virus ICP0 insufficient to affect cellular gene expression or cell survival.

Authors:  W E Hobbs; D E Brough; I Kovesdi; N A DeLuca
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption.

Authors:  S Müller; A Dejean
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  The major immediate-early gene ie3 of mouse cytomegalovirus is essential for viral growth.

Authors:  A Angulo; P Ghazal; M Messerle
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Herpes simplex virus type 1 ICP0 protein does not accumulate in the nucleus of primary neurons in culture.

Authors:  X p Chen; J Li; M Mata; J Goss; D Wolfe; J C Glorioso; D J Fink
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Role of human cytomegalovirus immediate-early proteins in cell growth control.

Authors:  J P Castillo; A D Yurochko; T F Kowalik
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Alphaherpesvirus proteins related to herpes simplex virus type 1 ICP0 affect cellular structures and proteins.

Authors:  J Parkinson; R D Everett
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

9.  Enhanced cytomegalovirus infection of developing brain independent of the adaptive immune system.

Authors:  Anthony N van den Pol; Jon D Reuter; Justin G Santarelli
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.